6,299 Shares in Guardant Health, Inc. $GH Purchased by Bosun Asset Management LLC

Bosun Asset Management LLC acquired a new stake in Guardant Health, Inc. (NASDAQ:GH) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 6,299 shares of the company’s stock, valued at approximately $328,000.

A number of other hedge funds also recently made changes to their positions in GH. Tema Etfs LLC boosted its stake in shares of Guardant Health by 11.7% during the 2nd quarter. Tema Etfs LLC now owns 11,350 shares of the company’s stock worth $591,000 after acquiring an additional 1,190 shares during the period. Guggenheim Capital LLC raised its stake in Guardant Health by 2.5% in the 2nd quarter. Guggenheim Capital LLC now owns 87,270 shares of the company’s stock valued at $4,542,000 after acquiring an additional 2,111 shares during the period. Invesco Ltd. lifted its holdings in Guardant Health by 27.3% during the 2nd quarter. Invesco Ltd. now owns 3,558,501 shares of the company’s stock valued at $185,184,000 after purchasing an additional 763,834 shares during the last quarter. Edgestream Partners L.P. lifted its holdings in Guardant Health by 147.3% during the 2nd quarter. Edgestream Partners L.P. now owns 50,519 shares of the company’s stock valued at $2,629,000 after purchasing an additional 30,094 shares during the last quarter. Finally, F m Investments LLC boosted its position in Guardant Health by 1.2% during the second quarter. F m Investments LLC now owns 39,099 shares of the company’s stock worth $2,035,000 after purchasing an additional 471 shares during the period. 92.60% of the stock is owned by institutional investors and hedge funds.

Guardant Health Stock Performance

NASDAQ:GH opened at $102.02 on Monday. Guardant Health, Inc. has a 52 week low of $29.91 and a 52 week high of $112.43. The firm’s 50-day simple moving average is $84.67 and its 200 day simple moving average is $63.43. The firm has a market cap of $12.86 billion, a price-to-earnings ratio of -31.78 and a beta of 1.58.

Guardant Health (NASDAQ:GH) last posted its quarterly earnings data on Wednesday, October 29th. The company reported ($0.39) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.48) by $0.09. During the same quarter in the prior year, the company posted ($0.88) earnings per share. The business’s revenue was up 38.5% compared to the same quarter last year. Sell-side analysts anticipate that Guardant Health, Inc. will post -2.9 EPS for the current year.

Insider Buying and Selling

In related news, insider John G. Saia sold 8,996 shares of the stock in a transaction that occurred on Friday, November 7th. The stock was sold at an average price of $96.25, for a total transaction of $865,865.00. Following the sale, the insider owned 43,172 shares of the company’s stock, valued at $4,155,305. This represents a 17.24% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. Also, CEO Helmy Eltoukhy sold 300,000 shares of the firm’s stock in a transaction on Tuesday, September 9th. The stock was sold at an average price of $59.45, for a total value of $17,835,000.00. Following the transaction, the chief executive officer owned 2,123,499 shares in the company, valued at approximately $126,242,015.55. This trade represents a 12.38% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. In the last ninety days, insiders have sold 368,228 shares of company stock valued at $24,835,525. 6.10% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several brokerages have recently weighed in on GH. Barclays increased their price objective on shares of Guardant Health from $70.00 to $85.00 and gave the company an “overweight” rating in a research report on Thursday, October 30th. William Blair reiterated an “outperform” rating on shares of Guardant Health in a research note on Thursday, September 25th. Wolfe Research raised shares of Guardant Health from a “peer perform” rating to an “outperform” rating and set a $75.00 price target on the stock in a report on Thursday, September 25th. TD Cowen raised their price objective on shares of Guardant Health from $63.00 to $72.00 and gave the stock a “buy” rating in a research report on Thursday, September 25th. Finally, Canaccord Genuity Group set a $100.00 price objective on Guardant Health in a report on Thursday, October 30th. Twenty-three investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average target price of $80.86.

Guardant Health Company Profile

Guardant Health, Inc, a precision oncology company, provides blood and tissue tests, data sets, and analytics in the United States and internationally. The company provides Guardant360; Guardant360 LDT; Guardant360 CDx Test; Guardant360 Response Test; Guardant360 TissueNext Test; GuardantINFINITY Test; GuardantConnect, an integrated software-based solution designed for clinical and biopharmaceutical customers to connect patients tested with assays with actionable alterations with potentially relevant clinical studies; GuardantOMNI Test for advanced stage cancer; and GuardantINFORM, an in-silico research platform for tumor evolution and treatment resistance across various biomarker-driven cancers.